Joint effects of epstein-barr virus and polymorphisms in interleukin-10 and interferon-γ on breast cancer risk

Journal of Infectious Diseases

Volumn 205, Issue 1, 2012, Pages 64-71

  He, Jian Rong ^a,b   Chen, Li Juan ^a   Su, Yi ^a   Cen, Yu Ling ^a   Tang, Lu Ying ^a   Yu, Dan Dan ^a   Chen, Wei Qing ^a   Wang, Shen Ming ^a   Song, Er Wei ^a   Ren, Ze Fang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU WOMEN AND CHILDREN S MEDICAL CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN 1; IMMUNOGLOBULIN A ANTIBODY; VIRUS CAPSID ANTIGEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CHINA; CONTROLLED STUDY; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FAMILY HISTORY; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTERFERON GAMMA GENE; INTERLEUKIN 10 GENE; MAJOR CLINICAL STUDY; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL;

ADULT; AGED; ANTIBODIES, VIRAL; BREAST NEOPLASMS; CASE-CONTROL STUDIES; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN A; INTERFERON-GAMMA; INTERLEUKIN-10; LOGISTIC MODELS; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84555195630     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir710     Document Type: Article

References (50)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108. (Pubitemid 40372904)
2. Yasui Y, Potter JD, Stanford JL, et al. Breast cancer risk and "delayed" primary Epstein-Barr virus infection. Cancer Epidemiol Biomarkers Prev 2001; 10:9-16. (Pubitemid 32106039)
3. Glaser SL, Hsu JL, GulleyML. Epstein-Barr virus and breast cancer: state of the evidence for viral carcinogenesis. Cancer Epidemiol Biomarkers Prev 2004; 13:688-97. (Pubitemid 38737855)
4. Amarante MK, Watanabe MA. The possible involvement of virus in breast cancer. J Cancer Res Clin Oncol 2009; 135:329-37.
5. Angeloni A, Farina A, Gentile G, et al. Epstein-Barr virus and breast cancer: search for antibodies to the novel BFRF1 protein in sera of breast cancer patients. J Natl Cancer Inst 2001; 93:560-1. (Pubitemid 32318440)
6. Richardson AK, Cox B, McCredie MR, et al. Cytomegalovirus, Epstein-Barr virus and risk of breast cancer before age 40 years: a case-control study. Br J Cancer 2004; 90:2149-52. (Pubitemid 38869721)
7. Joshi D, Quadri M, Gangane N, Joshi R, Gangane N. Association of Epstein-Barr virus infection (EBV) with breast cancer in rural Indian women. PLoS One 2009; 4:e8180.
8. Cox B, Richardson A, Graham P, Gislefoss RE, Jellum E, Rollag H. Breast cancer, cytomegalovirus and Epstein-Barr virus: a nested casecontrol study. Br J Cancer 2010; 102:1665-9.
9. Agborsangaya CB, Lehtinen T, Toriola AT, et al. Association between Epstein-Barr virus infection and risk for development of pregnancyassociated breast cancer: joint effect with vitamin D? Eur J Cancer 2011; 47:116-20.
10. Fachiroh J, Prasetyanti PR, Paramita DK, et al. Dried-blood sampling for Epstein-Barr virus immunoglobulin G (IgG) and IgA serology in nasopharyngeal carcinoma screening. J Clin Microbiol 2008; 46:1374-80. (Pubitemid 351563582)
11. He JR, Tang LY, Yu DD, et al. Epstein-Barr virus and breast cancer: serological study in a high-incidence area of nasopharyngeal carcinoma. Cancer Lett 2011; 309:128-36.
12. de-The G, Day NE, Geser A, et al. Sero-epidemiology of the Epstein-Barr virus: preliminary analysis of an international studyda review. IARC Sci Publ 1975; 11:3-16.
13. Thompson MP, Kurzrock R. Epstein-Barr virus and cancer. Clin Cancer Res 2004; 10:803-21. (Pubitemid 38198878)
14. Andersson J. Clinical and immunological considerations in Epstein-Barr virus-associated diseases. Scand J Infect Dis Suppl 1996; 100:72-82. (Pubitemid 26142629)
15. Miller CH, Maher SG, Young HA. Clinical use of interferon-gamma. Ann N Y Acad Sci 2009; 1182:69-79.
16. Shi Y, Lutz CT. Interferon-gamma control of EBV-transformed B cells: a role for CD81 T cells that poorly kill EBV-infected cells. Viral Immunol 2002; 15:213-25. (Pubitemid 34273450)
17. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19:683-765. (Pubitemid 32368050)
18. Moore KW, Vieira P, Fiorentino DF, Trounstine ML, Khan TA, Mosmann TR. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science 1990; 248:1230-4.
19. Morrison TE, Mauser A, Wong A, Ting JP, Kenney SC. Inhibition of IFN-gamma signaling by an Epstein-Barr virus immediate-early protein. Immunity 2001; 15:787-99. (Pubitemid 34008506)
20. Crawley E, Kay R, Sillibourne J, Patel P, Hutchinson I, Woo P. Polymorphic haplotypes of the interleukin-10 5' flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum 1999; 42:1101-8. (Pubitemid 29268946)
21. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997; 24:1-8. (Pubitemid 27050850)
22. Helminen M, Lahdenpohja N, Hurme M. Polymorphism of the interleukin-10 gene is associated with susceptibility to Epstein-Barr virus infection. J Infect Dis 1999; 180:496-9. (Pubitemid 30256334)
23. Helminen ME, Kilpinen S, Virta M, Hurme M. Susceptibility to primary Epstein-Barr virus infection is associated with interleukin-10 gene promoter polymorphism. J Infect Dis 2001; 184:777-80. (Pubitemid 32826430)
24. Yasui Y, Hamajima N, Nakamura T, El-Din NS, Tajima K, Potter JD. Association of Epstein-Barr virus antibody titers with a human IL-10 promoter polymorphism in Japanese women. J Autoimmune Dis 2008; 5:2.
25. Erdei E, Kang H, Meisner A, et al. Polymorphisms in cytokine genes and serum cytokine levels among New Mexican women with and without breast cancer. Cytokine 2010; 51:18-24.
26. Kim K, Cho SK, Sestak A, Namjou B, Kang C, Bae SC. Interferongamma gene polymorphisms associated with susceptibility to systemic lupus erythematosus. Ann Rheum Dis 2010; 69:1247-50.
27. Gauderman WJ. Sample size requirements for association studies of gene-gene interaction. Am J Epidemiol 2002; 155:478-84. (Pubitemid 34174160)
28. Howell WM, Rose-Zerilli MJ. Cytokine gene polymorphisms, cancer susceptibility, and prognosis. J Nutr 2007; 137:194S-9S. (Pubitemid 46052880)
29. Mok CC, Lanchbury JS, Chan DW, Lau CS. Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus. Arthritis Rheum 1998; 41:1090-5. (Pubitemid 28265833)
30. Giordani L, Bruzzi P, Lasalandra C, et al. Association of breast cancer and polymorphisms of interleukin-10 and tumor necrosis factor-alpha genes. Clin Chem 2003; 49:1664-7. (Pubitemid 37194223)
31. Gerger A, Renner W, Langsenlehner T, et al. Association of interleukin-10 gene variation with breast cancer prognosis. Breast Cancer Res Treat 2010; 119:701-5.
32. Kong F, Liu J, Liu Y, Song B, Wang H, Liu W. Association of interleukin-10 gene polymorphisms with breast cancer in a Chinese population. J Exp Clin Cancer Res 2010; 29:72.
33. Smith KC, Bateman AC, Fussell HM, Howell WM. Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur J Immunogenet 2004; 31:167-73. (Pubitemid 39049861)
34. Balasubramanian SP, Azmy IA, Higham SE, et al. Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review. BMC Cancer 2006; 6:188.
35. Bulpitt E, Baynes C, Dunning A, et al. Investigation of interleukin-10 and vascular endothelial growth factor single nucleotide polymorphisms in predisposition to breast cancer. Genes Immun 2004; 5:S53.
36. Scola L, Vaglica M, Crivello A, et al. Cytokine gene polymorphisms and breast cancer susceptibility. Ann N Y Acad Sci 2006; 1089:104-9. (Pubitemid 47092072)
37. Langsenlehner U, Krippl P, Renner W, et al. Interleukin-10 promoter polymorphism is associated with decreased breast cancer risk. Breast Cancer Res Treat 2005; 90:113-5. (Pubitemid 40568894)
38. Asadullah K, Sterry W, Volk HD. Interleukin-10 therapydreview of a new approach. Pharmacol Rev 2003; 55:241-69.
39. de Waal Malefyt R, Haanen J, Spits H, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991; 174:915-24.
40. Stewart JP, Rooney CM. The interleukin-10 homolog encoded by Epstein-Barr virus enhances the reactivation of virus-specific cytotoxic T cell and HLA-unrestricted killer cell responses. Virology 1992; 191: 773-82. (Pubitemid 23022482)
41. Kurilla MG, Swaminathan S, Welsh RM, Kieff E, Brutkiewicz RR. Effects of virally expressed interleukin-10 on vaccinia virus infection in mice. J Virol 1993; 67:7623-8. (Pubitemid 23343894)
42. Ruiz-Ruiz C, Munoz-Pinedo C, Lopez-Rivas A. Interferon-gamma treatment elevates caspase-8 expression and sensitizes human breast tumor cells to a death receptor-induced mitochondria-operated apoptotic program. Cancer Res 2000; 60:5673-80.
43. He YF, Wang XH, Zhang GM, Chen HT, Zhang H, Feng ZH. Sustained low-level expression of interferon-gamma promotes tumor development: potential insights in tumor prevention and tumor immunotherapy. Cancer Immunol Immunother 2005; 54:891-7. (Pubitemid 40991331)
44. HarigaiM, Kawamoto M, HaraM, Kubota T, Kamatani N,Miyasaka N. Excessive production of IFN-gamma in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator/B cell-activating factor/TNF ligand superfamily-13B. J Immunol 2008; 181:2211-9.
45. Pravica V, Perrey C, Stevens A, Lee JH, Hutchinson IV. A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production. Hum Immunol 2000; 61:863-6.
46. Schena FP, Cerullo G, Torres DD, et al. Role of interferon-gamma gene polymorphisms in susceptibility to IgA nephropathy: a family-based association study. Eur J Hum Genet 2006; 14:488-96.
47. Karakus N, Kara N, Ulusoy AN, Ozaslan C, Bek Y. Tumor necrosis factor alpha and beta and interferon gamma gene polymorphisms in Turkish breast cancer patients. DNA Cell Biol 2011; 30:371-7.
48. Kamali-Sarvestani E, Merat A, Talei AR. Polymorphism in the genes of alpha and beta tumor necrosis factors (TNF-alpha and TNF-beta) and gamma interferon (IFN-gamma) among Iranian women with breast cancer. Cancer Lett 2005; 223:113-9. (Pubitemid 40693715)
49. Gallicchio L, Chang H, Christo DK, et al. Single nucleotide polymorphisms in inflammation-related genes and mortality in a communitybased cohort in Washington County, Maryland. Am J Epidemiol 2008; 167:807-13. (Pubitemid 351451746)
50. Lee HC, Chang TY, Yeung CY, et al. Association of interferon-gamma gene polymorphisms in Taiwanese children with biliary atresia. J Clin Immunol 2010; 30:68-73.